Group 1 - JD Health reported a revenue of 17.12 billion yuan for Q3 2025, representing a year-on-year growth of 28.7%, with operating profit increasing by 125.3% to 1.24 billion yuan [1] - The company signed strategic cooperation agreements with major pharmaceutical companies including Eli Lilly, Innovent Biologics, and Bayer China, reinforcing its position as the first choice for the online launch of new specialty drugs [1] - JD Health also launched several health products online, including new generation vitamins and specialized medical foods, further establishing its market presence [1] Group 2 - In September 2025, JD Health formed a Smart Interconnection Ecological Alliance with leading medical device brands to create a comprehensive smart blood glucose management system, aiming to expand into other health monitoring areas [2] - A partnership was established with Huazhong University of Science and Technology to develop a leading smart outpatient service platform, enhancing patient experience through AI-driven services [2] Group 3 - Zhiyun Health announced a service cooperation agreement with JD Health to enhance online sales channels for its products, leveraging JD Health's extensive user base and platform resources [3] - The opening of online medical insurance purchasing rights is seen as a significant short-term catalyst for the industry, with JD Health positioned to benefit from this trend [3][4] - JD Health is recognized as a leading player in the pharmaceutical e-commerce sector, expected to gain from the increasing online penetration of pharmaceutical products and the opening of online medical insurance payment permissions [4]

JD Health International Inc. 地址為 為京東健康股份有限公司（「本公司」）股本中每股面值0.0000005美元的 股 普通股 （附註2） 的登記持有人，茲委任大會主席或 （附註3） 地址為 作為本人╱吾等受委代表並代表本人╱吾等出席本公司將於2025年12月8日（星期一）上午十時假座中國北京市經 濟技術開發區科創十一街20號院2號園區C座舉行的股東特別大會（「大會」）及其任何續會，並依照以下指示代表 本人╱吾等及以本人╱吾等名義就有關決議案投票 （附註4） 。 擬於2025年12月8日召開的股東特別大會適用之代理人委任表格 | | （附註6） 普通決議案 | （附註4） 贊成 | （附註4） 反對 | | --- | --- | --- | --- | | 1. | 確認、批准及追認本公司與JD.com, Inc.（「JD.com」）就提供技術和流量 | | | | | 支持服務訂立的日期為2025年9月29日的協議（「2026年技術和流量支持 | | | | | 服務框架協議」）及其項下擬進行的交易，更多詳情載於本公司日期為 | | | | | 2025年11月13日的通函（「通 ...

Group 1 - JD Health reported Q3 2025 revenue of 17.12 billion RMB, a year-on-year increase of 28.7%, and operating profit of 1.243 billion RMB, up 125.3% year-on-year [1] - The company signed strategic cooperation agreements with major pharmaceutical companies such as Eli Lilly, Innovent Biologics, Eisai China, and Bayer China, further establishing its position as the first choice for the online launch of new specialty drugs [1] - JD Health launched various health products, including new generation vitamins and specialized medical foods, achieving their online debut on the platform [1] Group 2 - In September 2025, JD Health partnered with Huazhong University of Science and Technology Tongji Medical College Affiliated Union Hospital to create a leading smart outpatient service platform [2] - The collaboration aims to implement the "JD Zhuoyi" AI product in outpatient services, establishing a comprehensive AI accompaniment system for patients [2] - Both parties will deepen cooperation in telemedicine, exploring new models of "Internet + healthcare" services [2]

Group 1 - JD Health reported Q3 2025 revenue of 17.12 billion RMB, a year-on-year increase of 28.7%, and operating profit of 1.243 billion RMB, up 125.3% year-on-year [1] - The company signed strategic cooperation agreements with major pharmaceutical companies such as Eli Lilly, Innovent Biologics, Eisai China, and Bayer China, further establishing its position as the "first station for the online launch of new specialty drugs" [1] - JD Health launched several health products online, including new drugs from major pharmaceutical companies and a new generation of vitamins and specialized medical foods [1] Group 2 - In September 2025, JD Health partnered with Huazhong University of Science and Technology Tongji Medical College Affiliated Union Hospital to create a leading smart outpatient service platform [2] - The collaboration aims to implement the "JD Zhaoyi" AI product in outpatient services, establishing a full-process AI accompaniment system for patients [2] - Both parties will deepen cooperation in telemedicine and explore new models of "Internet + healthcare" services [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責任。 JD Health International Inc. 京東健康股份有限公司 茲通告京东健康股份有限公司（「本公司」）將於2025年12月8日（星期一）上午十時三十分 假座中國北京市經濟技術開發區科創十一街20號院2號園區C座舉行股東特別大會（「股 東特別大會」），以考慮及酌情通過下列普通決議案（不論有否修訂）： 普通決議案 「動議： 1 1. 確認、批准及追認本公司與JD.com, Inc.（「JD.com」）就提供技術和流量支持服務訂立 的日期為2025年9月29日的協議（「2026年技術和流量支持服務框架協議」）及其項下擬 進行的交易，更多詳情載於本公司日期為2025年11月13日的通函（「通函」），及一般 及無條件授權本公司任何一名董事（「董事」）就實行2026年技術和流量支持服務框架 協議及其項下擬進行的交易及╱或使其生效或其他相關事項進行其認為屬必要、適 宜、適當或權宜的一切有關進一步行動及 ...

此乃要件 請即處理 閣下如對本通函任何方面或應採取之行動有任何疑問，應諮詢股票經紀或其他註冊證券交易商、 銀行經理、律師、專業會計師或其他專業顧問。 閣下如已出售或轉讓名下所有京东健康股份有限公司之股份，應立即將本通函連同隨附之代表 委託表格送交買主或承讓人或經手買賣或轉讓之銀行、股票經紀或其他代理商，以便轉交買主 或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本通函全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 JD Health International Inc. 京東健康股份有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6618（港幣櫃台）及86618（人民幣櫃台）） (1)續簽現有持續關連交易 及 (2)股東特別大會通告 獨立董事委員會及獨立股東之 獨立財務顧問 獨立董事委員會致獨立股東之函件載於本通函第23頁。嘉林資本函件載於本通函第24至46頁， 當中載有其向獨立董事委員會及獨立股東提供之意見。 京东健康股份有限公司將於2025年12月8日（星期一）上午十時三十分假座 ...

JD Health International Inc. 京東健康股份有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6618（港幣櫃台）及86618（人民幣櫃台）） 內幕消息 2025 年第三季度之未經審計最新資料 本公告乃由京东健康股份有限公司（「本公司」或「京東健康」，連同其子公司及關聯併表 實體統稱「本集團」）根據香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規 則」）第13.09條及香港法例第571章證券及期貨條例第XIVA部項下的內幕消息條文（定義 見上市規則）而刊發。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責任。 業務最新資料 2025年第三季度，京東健康與禮來、信達生物、衛材中國及拜耳中國等知名藥企簽署戰 略合作協定。衛材藥企旗下原研新藥達衛可® （萊博雷生片）、恒瑞旗下乾眼症新藥恆沁® （全氟己基辛烷滴眼液）、拜耳旗下達喜® 乳果糖等新藥也選擇在京東健康全網首發，繼 續鞏固京東健康「新特藥全網首發第一站」心智。除藥 ...

Core Viewpoint - The collaboration between Zhiyun Health and JD Health aims to enhance online sales and service channels for Livermore tablets and other P2M pipeline products, providing patients with a more convenient purchasing experience and comprehensive health management services [1] Group 1: Partnership Details - Zhiyun Health has signed a service cooperation agreement with JD Health to expand the online sales and service channels for its products [1] - JD Health is recognized as the largest pharmaceutical e-commerce platform in China, offering a vast user base and extensive platform resources [1] - The partnership represents a strong alliance that will effectively promote high-quality and cost-effective medications [1] Group 2: Company Strengths - Zhiyun Health is a leading platform in chronic disease management, possessing a unique product pipeline and expertise in patient management [1] - The collaboration leverages the strengths of both companies to enhance patient access to medications and health services [1]

Core Viewpoint - The collaboration between Zhiyun Health (09955) and JD Health (06618) aims to enhance online sales and service channels for Livermore tablets and other P2M pipeline products, providing patients with a more convenient purchasing experience and comprehensive health management services [1] Group 1: Partnership Details - Zhiyun Health has entered into a service cooperation agreement with JD Health to expand the online sales and service channels for its products [1] - JD Health, as the largest pharmaceutical e-commerce platform in China, offers a vast user base and extensive platform resources [1] - The partnership represents a strong alliance that will effectively promote high-quality and cost-effective medications [1] Group 2: Market Implications - The collaboration is expected to leverage the unique product pipeline and patient management expertise of Zhiyun Health, enhancing the overall service offering [1] - This strategic move aligns with the growing trend of digital health solutions and e-commerce in the pharmaceutical industry [1]

Core Viewpoint - The collaboration between Zhiyun Health and JD Health aims to enhance online sales and service channels for Lifemin tablets and other P2M pipeline products, providing patients with a more convenient purchasing experience and comprehensive health management services [1] Group 1: Partnership Details - Zhiyun Health has entered into a service cooperation agreement with JD Health to expand the online sales and service channels for its products [1] - JD Health is recognized as the largest pharmaceutical e-commerce platform in China, boasting a vast user base and extensive platform resources [1] - The partnership signifies a strong alliance that will effectively promote high-quality and cost-effective medications [1] Group 2: Company Strengths - Zhiyun Health is a leading platform in chronic disease management, possessing unique product pipelines and professional capabilities in doctor-patient management [1] - The collaboration leverages the strengths of both companies to enhance patient access to medications and health services [1]